EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment

Grace Lai-Hung Wong iD, Edward Gane iD, Calvin Q Pan iD, Scott Fung iD, Mang M Ma iD, Namiki Izumi iD, Shalimar iD, Seng Gee Lim iD, Wan-Long Chuang iD, Rajiv Mehta iD, Young-Suk Lim iD, Leland J Yee iD und 4 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70327 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Grace Lai-Hung Wong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Adenine, Antiviral Agents, Hepatitis B, Chronic, Tenofovir. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir alafenamide (TAF) has shown non‐inferior efficacy to tenofovir disoproxil fumarate (TDF), with superior bone and renal safety.

Aim

To characterise 5‐year TAF efficacy and safety in patients of East Asian ethnicity from pivotal Phase 3 studies.

Methods

Patients were randomised (2:1) to receive TAF or TDF for up to 3 years of double‐blind treatment, followed by open‐label TAF. Patients either continued TAF or switched from TDF to TAF at Week 96 (TDF → TAF 3 years) or Week 144 (TDF → TAF 2 years) of treatment. Efficacy endpoints (virologic, biochemical and serologic) and safety were assessed.

Results

Among 591 patients of East Asian ethnicity (TAF, n = 401; TDF → TAF 3 years, n = 84; TDF → TAF 2 years, n = 106), high rates of virologic control were achieved (89%, 94% and 92%, respectively) at Year 5 (missing = failure analysis). At Year 5, rates of alanine aminotransferase normalisation (85%, 90% and 78%) and hepatitis B e antigen loss (36%, 43% and 44%) were similar. Following the switch from TDF to TAF, changes in fasting lipid parameters were consistent with removal of the known lipid‐lowering effect of TDF. However, changes in the total cholesterol to high‐density lipoprotein ratio (marker of cardiovascular risk) were minimal and comparable in all groups by Year 5. Renal and bone parameters improved after switching.

Conclusions

Through 5 years, rates of virologic suppression were high in East Asian patients treated with TAF or switched from TDF to TAF. TAF and TDF were well tolerated, with improved renal and bone safety observed in patients switching from TDF to TAF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAntiviral AgentsHepatitis B, ChronicTenofovirAdultFemaleHumansMaleMiddle AgedAlanineDouble-Blind MethodEast Asian PeopleTreatment Outcome

Stichwörter der Autor:innen

ALT normalisationhepatitis Btenofovir alafenamidetenofovir disoproxil fumarate

Substanzen

AdenineAlanineAntiviral AgentsTenofovirtenofovir alafenamide

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Faculty of Medicine, University of Auckland, Auckland, New Zealand.
  • Division of Hepatology, Department of Medicine, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, New York University Grossman School of Medicine, New York City, New York, USA.
  • Department of Medicine, Toronto Center for Liver Disease, University of Toronto, Toronto, Ontario, Canada.
  • University of Alberta, Edmonton, Alberta, Canada.

ORCID-Profile: Grace Lai-Hung Wong, Edward Gane, Calvin Q Pan, Scott Fung, Mang M Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan-Long Chuang, Rajiv Mehta, Young-Suk Lim, Leland J Yee, John F Flaherty, Frida Abramov, Maria Buti

Förderung

  • Gilead Sciences

Zitieren

APA

Wong, G. L., Gane, E., Pan, C. Q., Fung, S., Ma, M. M., Izumi, N., Shalimar, Lim, S. G., Chuang, W. L., Mehta, R., Lim, Y. S., Yee, L. J., Flaherty, J. F., Abramov, F., Wang, H., & Buti, M. (2026). Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70327

Vancouver

Wong GL, Gane E, Pan CQ, Fung S, Ma MM, Izumi N, et al. Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70327

BibTeX
@article{Wong2026,
  author = {Wong, Grace Lai-Hung and Gane, Edward and Pan, Calvin Q and Fung, Scott and Ma, Mang M and Izumi, Namiki and Shalimar and Lim, Seng Gee and Chuang, Wan-Long and Mehta, Rajiv and Lim, Young-Suk and Yee, Leland J and Flaherty, John F and Abramov, Frida and Wang, Hongyuan and Buti, Maria},
  title = {Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70327}
}
Kostenlos starten →